Thoradepenbenzene is listed in China for treatment of Huntington's disease (HD)

Theof adeutolbenine tablets is a small molecule oral inhibitor targeted at VMAT-2 (ves monoicularamine transporter 2), first developed by Apexus Pharmaceuticals, a thorium drug for the available Huntington treatment Xenazine (Tetrabenazine), with a synthetic route reference US2014066740onApril, 2017, Teva announced that its Huntington's disease drugSD-809approved by theFDA, namedAUSTEDOAUSTEDObecame the first thorium drug approved by theFDASD-809is a small-molecule oral inhibitor targeted VMAT-2 and is a thorium drug tetrabenazine, a listed Huntington drug After the geniquin, pharmacokinetic scars are improved and the half-life is significantly longer, allowing for lower therapeutic doses the SD-809 was originally developed by Auspex , and in March 2015 , , teva spent 3.
billion to acquire the Auspex 4.
months after the publication of the SD-809 Phase III clinical data On April 3, 2017, the world's first radon drug, austedo (deutetranazibene) of thorium benina, was approved by the U.S FDA for the treatment of abnormal involuntary movements caused by Huntington's disease Austedo, a
of delayed motor disorders and dance disorders associated with Huntington's disease, also received FDA approval for delayed motor disorders in adults On December 27, 2019, Teva Pharmaceuticals of Israel submitted an application for a new drug listing (NDA) in China, which was accepted by the CDE Teva submits relevant information in accordance with the Procedures for the Review and Approval of Clinically Urgent Overseas New Drugs, and directly submits an application for listing Prior to the tablets of thoradebutananadin were selected in CDE's first clinically urgent overseas drug list Delayed motor disorder is a motor impairment disorder that affects about half a million people in the United States "Dance symptoms" are the most obvious symptoms of Huntington's disease, with nearly 90 percent of Huntington's patients experiencing convulsions and involuntary movements in the upper and lower limbs, faces or bodies during the illness The expansion of Austedo (Deustybenazine) indications is based on clinical trial data that can significantly reduce late-onterm motor disorders while maintaining good safety and tolerance in the United States, the 6mg, 60-piece Austedo thain-benapen tablet sells for about $4,048 About Deutetrabenazine Deutetrabenazine (formerly known as SD-809) is a class of cystic monoamine transporter 2 (ves monolyamine transporter 2, VMAT2) inhibitor Neurotransmitters are stored in neurons in the form of cystic bubbles, and the storage of certain neurotransmitters is controlled by the cystic monoamine transporter (VMAT) Numerous studies have demonstrated the significance of VMAT as a target for drug therapy in various neuropathic states Many drugs that target VMAT often act as inhibitors, including VMAT2 inhibitortetrabenazine, which is used to treat movement disorders associated with Huntington's disease and other motor disorders author: MedSci Source: MedSci Original